These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36647946)

  • 1. Efficacy and adverse reactions of intra-arterial chemotherapy in patients with bladder cancer: A systematic review and meta-analysis.
    Ji J; Yao Y; Guan F; Sun L; Zhang G
    J Cancer Res Ther; 2022 Dec; 18(7):1884-1893. PubMed ID: 36647946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of intra-arterial chemotherapy in high-risk non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    You C; Li X; Du Y; Wang H; Zhang X; Wei T; Wang A
    PeerJ; 2021; 9():e12248. PubMed ID: 34692255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-arterial chemotherapy combined with intravesical chemotherapy compared with intravesical BCG immunotherapy retrospectively in high-risk non-muscle-invasive bladder cancer after transurethral resection of the bladder tumor.
    Huang B; Huang G; Li W; Chen L; Mao X; Chen J
    J Cancer Res Clin Oncol; 2021 Jun; 147(6):1781-1788. PubMed ID: 33222014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intra-arterial chemotherapy combined with intravesical chemotherapy is effective in preventing recurrence in non-muscle invasive bladder cancer.
    Lian F; Chen W; Liu Y; Shen L; Fan W; Cui W; Zhao Y; Li J; Wang Y
    J Cancer Res Clin Oncol; 2019 Jun; 145(6):1625-1633. PubMed ID: 30900154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of intra-arterial chemotherapy combined with intravesical chemotherapy for high-risk non-muscle invasive bladder cancer: A protocol for a systematic review and meta-analysis.
    Li X; Ma H; Shu K; Wang L; Ding D
    Medicine (Baltimore); 2019 Dec; 98(51):e18516. PubMed ID: 31861039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of intra-arterial chemotherapy combined with intravesical chemotherapy in T1G3 bladder cancer when compared with intravesical chemotherapy alone after bladder-sparing surgery: a retrospective study.
    Huang B; Zheng J; Yao Z; Fan W; Qiu S; Chen L; Chen J
    World J Urol; 2019 May; 37(5):823-829. PubMed ID: 30191393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of intraarterial chemotherapy for non muscle invasive bladder cancer: Promising alternative therapy in high tuberculosis burden countries.
    Rahman ZA; Hidayatullah F; Lim J; Hakim L
    Arch Ital Urol Androl; 2024 Feb; 96(1):12154. PubMed ID: 38363237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy of Intra-Arterial Plus Intravesical Chemotherapy
    Zhou Z; Cui Y; Huang S; Chen Z; Zhang Y
    Front Oncol; 2021; 11():651657. PubMed ID: 34123803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immediate post-transurethral resection of bladder tumor intravesical chemotherapy prevents non-muscle-invasive bladder cancer recurrences: an updated meta-analysis on 2548 patients and quality-of-evidence review.
    Perlis N; Zlotta AR; Beyene J; Finelli A; Fleshner NE; Kulkarni GS
    Eur Urol; 2013 Sep; 64(3):421-30. PubMed ID: 23830475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Intra-Arterial Plus Intravesical Chemotherapy for High-Risk Non-Muscle-Invasive Bladder Cancer: A Pooled Analysis.
    Cheng C; Qiu D; Chen J; Zu X; Liu J; Li H; Hu J; Yi Z; He T; Chen Z; Cui Y
    Front Pharmacol; 2021; 12():707271. PubMed ID: 34603020
    [No Abstract]   [Full Text] [Related]  

  • 11. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intra-arterial chemotherapy plus BCG, a promising combination adjuvant treatment for high-risk NMIBC.
    Luo S; Wu Y; Yang R; Huang G; Lei J; Liu J; Lin S; Chen L; Chen J; Huang B
    Urol Oncol; 2024 Feb; 42(2):30.e9-30.e16. PubMed ID: 37867055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Visualization Methods for First Transurethral Resection of Bladder Tumour in Suspected Non-muscle-invasive Bladder Cancer: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(12):1-123. PubMed ID: 34484486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of intra-arterial chemotherapy combined with intravesical chemotherapy against intravesical chemotherapy alone after transurethral resection of bladder tumor in T1-staged Grade 3 bladder cancer.
    Huang B; Wang H; Lin H; Yao Z; Zheng J; Fan W; Qiu S; Chen L; Chen J
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):487-494. PubMed ID: 30539282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis.
    Chen Q; Zhang B; Dong Y; Mo X; Zhang L; Huang W; Jiang H; Xia J; Zhang S
    BMC Cancer; 2018 Apr; 18(1):486. PubMed ID: 29703164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluating primary intra-arterial chemotherapy versus intravenous plus intra-arterial chemotherapy for advanced intraocular retinoblastoma.
    Chen Q; Zhang B; Dong Y; Mo X; Zhang L; Xia J; Zhang J; Zhang S
    Cancer Chemother Pharmacol; 2020 Apr; 85(4):723-730. PubMed ID: 32123960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Restaging Transurethral Resection of Bladder Tumor on Survival Parameters in T1 Nonmuscle-Invasive Bladder Cancer: Systematic Review and Meta-Analysis.
    Krajewski W; Nowak Ł; Poletajew S; Tukiendorf A; Moschini M; Mari A; Di Trapani E; Xylinas E; Kiełb P; Wełna M; Zdrojowy R
    J Endourol; 2020 Aug; 34(8):795-804. PubMed ID: 32336149
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis.
    Huang D; Jin YH; Weng H; Huang Q; Zeng XT; Wang XH
    Front Oncol; 2019; 9():121. PubMed ID: 30881921
    [No Abstract]   [Full Text] [Related]  

  • 19. Risk-Based Assessment Of the Impact Of Intravesical Therapy on Recurrence-Free Survival Rate Following Resection of Suspected Low-grade, Non-muscle-invasive Bladder Cancer (NMIBC): A Southwest Oncology Groups (SWOG) S0337 Posthoc Analysis.
    Corsi NJ; Messing EM; Sood A; Keeley J; Bronkema C; Rakic N; Jamil M; Dalela D; Arora S; Piontkowski AJ; Majdalany SE; Butaney M; Rakic I; Li P; Menon M; Rogers CG; Abdollah F
    Clin Genitourin Cancer; 2022 Dec; 20(6):e498-e505. PubMed ID: 35871040
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of systemic chemotherapy and intra-arterial chemotherapy with/without radiotherapy for bladder preservation or as neo-adjuvant therapy in patients with muscle-invasive bladder cancer: a single-centre study of 163 patients.
    Miyata Y; Nomata K; Ohba K; Matsuo T; Hayashi N; Sakamoto I; Uetani M; Sakai H
    Eur J Surg Oncol; 2015 Mar; 41(3):361-7. PubMed ID: 25312685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.